Niemann-Pick Disease
Niemann-Pick disease refers to a group of rare inherited conditions that affect the body's ability to process certain fats (lipids).
Overview
Niemann-Pick disease refers to a group of rare inherited conditions that affect the body's ability to process certain fats (lipids). These fats build up in cells, particularly in the liver, spleen, lungs and brain. There are different types of Niemann-Pick disease, including types A, B and C. Severity and symptoms vary depending on the type.
Causes and Genetics
Types A and B are caused by mutations in the SMPD1 gene, leading to deficiency of an enzyme called acid sphingomyelinase. Type C is caused by mutations in the NPC1 or NPC2 genes, affecting the movement of cholesterol and other fats inside cells. Most forms are inherited in an autosomal recessive pattern, meaning a child must inherit two altered copies of the gene (one from each parent) to develop the condition.
Symptoms and Features
Symptoms depend on the type and may begin in infancy, childhood or adulthood.
Characteristic Symptoms and Features
- Enlarged liver and spleen
- Poor growth
- Feeding difficulties
- Developmental delay in more severe forms
Other Associated Symptoms and Features
- Neurological symptoms such as difficulty with balance and coordination, problems with eye movements, speech difficulties and swallowing problems, particularly in Type C
- Some individuals may develop lung problems or progressive cognitive decline
Type A is usually severe in infancy, Type B often has little or no neurological involvement, and Type C primarily affects the nervous system.
Treatment
Nutritional support; physiotherapy; speech and swallowing support; and monitoring of liver and lung function. Care is usually coordinated through specialist metabolic or neurology centres.
Research and Future Directions
Ongoing research is focused on enzyme replacement therapies, substrate reduction therapies and gene-based treatments. Clinical trials are exploring new approaches aimed at reducing lipid build-up and slowing neurological progression. Improved understanding of disease mechanisms continues to guide development of targeted treatments.